• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $1,658 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-104 Mln

Kura Oncology Inc. (KURA) Share Price

$21.38

As on 28-Feb-2024 16:00 EST

up-down-arrow $-0.38-1.75%

  • Prev Close info

    $21.76

  • Day's Openinfo

    $21.75

  • Today's Highinfo

    $22.53

  • Today's Lowinfo

    $21.35

  • Today's Volumeinfo

    1,647,472

  • 52 Week rangeinfo

    $7.41 - 22.92

Please wait...

Kura Oncology Inc. (KURA) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Kura Oncology (KURA)
48.68 18.91 130.89 80.27 -8.60 6.38 --
S&P BSE Sensex
0.09 2.27 9.60 21.95 13.77 15.03 13.17
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 28-Feb-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Kura Oncology (KURA)
15.87 -11.36 -57.13 137.53 -2.07 -8.19 159.32
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Kura Oncology Inc. (KURA) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Kura Oncology Inc. (KURA)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Kura Oncology Inc. (KURA)

        Chairman, CEO & President

        Dr. Troy Edward Wilson J.D., Ph.D.

        Chief Operating Officer

        Ms. Kathleen Ford

        Headquarters

        San Diego, CA

        FAQs for Kura Oncology Inc. (KURA)

        The total asset value of Kura Oncology Inc. (KURA) stood at $ 501 Mln as on 30-Sep-23

        The share price of Kura Oncology Inc. (KURA) is $21.38 (NASDAQ) as of 28-Feb-2024 16:00 EST. Kura Oncology Inc. (KURA) has given a return of -8.6% in the last 3 years.

        Kura Oncology Inc. (KURA) has a market capitalisation of $ 1,658 Mln as on 28-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Kura Oncology Inc. (KURA) is 3.67 times as on 28-Feb-2024, a 0.23% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Kura Oncology Inc. (KURA) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Kura Oncology Inc. (KURA) and enter the required number of quantities and click on buy to purchase the shares of Kura Oncology Inc. (KURA).

        Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Address: 12730 High Bluff Drive, San Diego, CA, United States, 92130

        The CEO & director of Dr. Troy Edward Wilson J.D., Ph.D.. is Kura Oncology Inc. (KURA), and CFO & Sr. VP is Ms. Kathleen Ford.

        The promoters of Kura Oncology Inc. (KURA) have pledged 0% of the total equity as on Sep-23.

        Kura Oncology Inc. (KURA) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.02
        Dividend yield(%)
        0

        No, TTM profit after tax of Kura Oncology Inc. (KURA) was $-104 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $1,657.88 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-104.36 Mln
        • Cash date-information $452.59 Mln
        • Total Debt info $17.42 Mln
        • Insider's Holding 1.75%
        • Liquidity liquidity High
        • 52 Week range week-range $7.41 - 22.92
        • Shares outstanding share-outstanding 76,137,000
        • 10 Years Aggregate:

          CFO: $-577.47 Mln

          EBITDA: $-585.27 Mln

          Net Profit: $-711.24 Mln

        About The Company

        • IPO Date 22-Sep-2015
        • Chairman, CEO & President Dr. Troy Edward Wilson J.D., Ph.D.
        • Chief Operating Officer Ms. Kathleen Ford
        • Listing key-listing NASDAQ: KURA
        • Country United States
        • Headquarters headquarters San Diego, CA
        • Website website https://kuraoncology.com
        • Business

          Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates...  are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Address: 12730 High Bluff Drive, San Diego, CA, United States, 92130  Read more

        share-fund-plan-icon